Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Condition(s):Renal Cancer; Kidney Cancer; Renal Cell Carcinoma; Inferior Vena Cava ThrombosisLast Updated:January 30, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Renal Cancer; Kidney Cancer; Renal Cell Carcinoma; Inferior Vena Cava ThrombosisLast Updated:January 30, 2024Recruiting
Condition(s):Renal InsufficiencyLast Updated:June 1, 2007Completed
Condition(s):Acute Kidney InjuryLast Updated:May 22, 2019Completed
Condition(s):UremiaLast Updated:July 9, 2013Completed
Condition(s):Renal Cell CarcinomaLast Updated:May 12, 2023Recruiting
Condition(s):Acute Kidney InjuryLast Updated:March 29, 2023Recruiting
Condition(s):Postoperative Hemorrhage; Postoperative Anemia; Postoperative Blood LossLast Updated:March 6, 2024Not yet recruiting
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:January 11, 2023Recruiting
Condition(s):Carcinoma, Renal Cell; Prostatic NeoplasmsLast Updated:November 18, 2019Completed
Condition(s):Nephrosis, LipoidLast Updated:June 1, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.